Merck and Moderna Initiated Phase 3 Study Evaluating V940 in Combination with KEYTRUDA® for Patients with Resected High-Risk Melanoma
July 26, 2023
0
Merck and Moderna Inc Announcement Merck (MRK) and Moderna Inc (MRNA . . . This content is for paid subscribers. Please click here to subscribe or here to log in.